Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma

Shimpei Yamashita ¹, Shuzo Hamamoto ², Junya Furukawa ³

⁰Department of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-0012, Japan. keito608@wakayama-med.ac.jp.

Scientific Reports +

|

May 29, 2024

View abstract on PubMed

Summary

The pre-treatment FAN score predicts outcomes for metastatic renal cell carcinoma (RCC) patients receiving nivolumab plus ipilimumab. A high FAN score (≥2) indicates a poorer prognosis for survival, including second progression-free survival, cancer-specific survival, and overall survival.

Area Of Science

Oncology
Immunotherapy
Renal Cell Carcinoma Research

Background

The FAN score's prognostic value is known for urothelial carcinoma treated with immune checkpoint inhibitors.
Its impact on metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab is not well-established.

Purpose Of The Study

To investigate the association between the pre-treatment FAN score and prognostic outcomes in mRCC patients receiving nivolumab plus ipilimumab.
To determine if the FAN score can predict survival in this patient population.

Main Methods

Retrospective analysis of 154 mRCC patients treated with nivolumab plus ipilimumab.
Evaluation of pre-treatment FAN scores (0, 1, 2, 3) and their correlation with progression-free survival, second progression-free survival (PFS2), cancer-specific survival (CSS), and overall survival (OS).
Multivariable Cox proportional hazard analyses were performed.

Main Results

Progression-free survival did not significantly differ across FAN score groups.
However, FAN score ≥2 was significantly associated with poorer PFS2, CSS, and OS compared to FAN score 0.
Specifically, HRs for poor PFS2, CSS, and OS were 2.43, 2.71, and 2.42, respectively, for FAN score ≥2 versus 0.

Conclusions

The pre-treatment FAN score is a significant independent predictor of poor prognosis in mRCC patients treated with nivolumab plus ipilimumab.
A high FAN score (≥2) identifies patients with worse outcomes, including reduced PFS2, CSS, and OS.
This finding aids in risk stratification and personalized treatment strategies for mRCC.

Related Concept Videos

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.